Payment overview · 2025
General Payments
$697.04
28 reported records · 13 companies
Healthcare provider profile · identity verified
Robert Dewitt, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ALVIN, TX · NPI 1972589737
Verified facts
What the public records show
CMS Open Payments records show Robert Dewitt, MD received $697.04 in general payments during 2025 across 28 reported records.
HARMONY BIOSCIENCES LLC accounted for 18.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $130.76 | 18.8% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $121.35 | 17.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $112.52 | 16.1% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.25 | 7.3% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $47.84 | 6.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.28 | 6.8% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $42.64 | 6.1% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $31.82 | 4.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.89 | 4.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.86 | 3.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.30 | 3.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.73 | 2.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.80 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $697.04 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $130.76 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $121.35 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $112.52 | 7 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $47.84 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $47.28 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $42.64 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $31.82 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $30.89 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.86 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.86 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.30 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $22.59 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $22.59 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.80 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.80 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 65 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 63 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 49 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
65 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
50 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
49 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
144 | 52 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 596 | 251 |
| Amlodipine Besylate | Amlodipine Besylate | 529 | 216 |
| Lisinopril | Lisinopril | 404 | 161 |
| Levothyroxine Sodium | Levothyroxine Sodium | 401 | 163 |
| Gabapentin | Gabapentin | 358 | 137 |
| Furosemide | Furosemide | 306 | 116 |
| Pantoprazole Sodium | Pantoprazole Sodium | 304 | 139 |
| Trazodone Hcl | Trazodone Hcl | 303 | 84 |
| Losartan Potassium | Losartan Potassium | 272 | 129 |
| Clopidogrel | Clopidogrel Bisulfate | 226 | 89 |
| Metformin Hcl | Metformin Hcl | 220 | 105 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 216 | 80 |
| Sertraline Hcl | Sertraline Hcl | 206 | 80 |
| Metoprolol Tartrate | Metoprolol Tartrate | 199 | 93 |
| Pravastatin Sodium | Pravastatin Sodium | 198 | 84 |
| Omeprazole | Omeprazole | 193 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 193 | 77 |
| Buspirone Hcl | Buspirone Hcl | 191 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 182 | 78 |
| Carvedilol | Carvedilol | 174 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 172 | 77 |
| Alprazolam | Alprazolam | 159 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 151 | 56 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 150 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 147 | 67 |
| Eliquis | Apixaban | 144 | 52 |
| Diazepam | Diazepam | 143 | 20 |
| Ozempic | Semaglutide | 134 | 39 |
| Potassium Chloride | Potassium Chloride | 128 | 47 |
| Warfarin Sodium | Warfarin Sodium | 121 | 20 |
| Atenolol | Atenolol | 115 | 45 |
| Allopurinol | Allopurinol | 114 | 46 |
| Meloxicam | Meloxicam | 112 | 48 |
| Glimepiride | Glimepiride | 110 | 50 |
| Clonazepam | Clonazepam | 106 | 14 |
| Simvastatin | Simvastatin | 97 | 41 |
| Quetiapine Fumarate | Quetiapine Fumarate | 95 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 94 | 28 |
| Famotidine | Famotidine | 87 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 29 |
| Clonidine Hcl | Clonidine Hcl | 83 | 31 |
| Metformin Hcl Er | Metformin Hcl | 83 | 36 |
| Montelukast Sodium | Montelukast Sodium | 81 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 29 |
| Oxybutynin Chloride | Oxybutynin Chloride | 77 | 29 |
| Amoxicillin | Amoxicillin | 70 | 60 |
| Fluoxetine Hcl | Fluoxetine Hcl | 70 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 41 |
| Farxiga | Dapagliflozin Propanediol | 65 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 65 | 49 |
| Xarelto | Rivaroxaban | 65 | 18 |
| Jardiance | Empagliflozin | 63 | 25 |
| Spironolactone | Spironolactone | 60 | 19 |
| Donepezil Hcl | Donepezil Hcl | 59 | 24 |
| Pregabalin | Pregabalin | 58 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 56 | 18 |
| Lorazepam | Lorazepam | 55 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 54 | 26 |
| Nystatin | Nystatin | 53 | 23 |
| Tresiba Flextouch U-100 | Insulin Degludec | 53 | 19 |
| Finasteride | Finasteride | 51 | 15 |
| Ezetimibe | Ezetimibe | 50 | 16 |
| Ibandronate Sodium | Ibandronate Sodium | 50 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | 12 |
| Mounjaro | Tirzepatide | 49 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 49 | 33 |
| Symbicort | Budesonide/Formoterol Fumarate | 49 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 47 | 19 |
| Alendronate Sodium | Alendronate Sodium | 46 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | 13 |
| Baclofen | Baclofen | 46 | 21 |
| Azithromycin | Azithromycin | 45 | 36 |
| Myrbetriq | Mirabegron | 45 | 16 |
| Prednisone | Prednisone | 45 | 23 |
| Testosterone Cypionate | Testosterone Cypionate | 45 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 35 |
| Levetiracetam | Levetiracetam | 43 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | 24 |
| Temazepam | Temazepam | 42 | suppressed |
| Methylprednisolone | Methylprednisolone | 41 | 38 |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 19 |
| Tramadol Hcl | Tramadol Hcl | 41 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | 13 |
| Fluconazole | Fluconazole | 38 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Cephalexin | Cephalexin | 37 | 26 |
| Glipizide | Glipizide | 37 | 13 |
| Promethazine Hcl | Promethazine Hcl | 37 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 23 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 34 | suppressed |
| Mirtazapine | Mirtazapine | 34 | 15 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Nifedipine Er | Nifedipine | 33 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | 13 |
| Benazepril Hcl | Benazepril Hcl | 31 | 12 |
| Lactulose | Lactulose | 31 | 16 |
| Topiramate | Topiramate | 31 | suppressed |
| Brilinta | Ticagrelor | 30 | suppressed |
| Estradiol | Estradiol | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | 13 |
| Diclofenac Potassium | Diclofenac Potassium | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 29 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 28 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 15 |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Gemfibrozil | Gemfibrozil | 27 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | 11 |
| Jantoven | Warfarin Sodium | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | 13 |
| Memantine Hcl | Memantine Hcl | 25 | 11 |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | 11 |
| Levofloxacin | Levofloxacin | 23 | 19 |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 14 |
| Bumetanide | Bumetanide | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | 11 |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 16 |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Eplerenone | Eplerenone | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Clotrimazole | Clotrimazole | 15 | 12 |
| Digoxin | Digoxin | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $697.04 · 28 records | HARMONY BIOSCIENCES LLC | AREXVY, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FARXIGA, JARDIANCE, KRYSTEXXA, Korlym, MOUNJARO, OTEZLA, PREVNAR 20, REPATHA, SHINGRIX, WAKIX, WATCHMAN Access System, XIFAXAN, YUPELRI, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error